We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
CHOP plus etoposide and gemcitabine (CHOP-EG) as front-line chemotherapy for patients with peripheral T cell lymphomas.
- Authors
Jong Gwang Kim; Sang Kyun Sohn; Yee Soo Chae; Dong Hwan Kim; Jin Ho Baek; Kyu Bo Lee; Je-Jung Lee; Ik-Joo Chung; Hyeoung-Joon Kim; Deok-Hwan Yang; Won-Sik Lee; Young-Don Joo; Chang-Hak Sohn
- Abstract
Objective: The present study evaluated the feasibility of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) plus etoposide and gemcitabine (CHOP-EG) as front-line chemotherapy in patients with peripheral T cell lymphomas (PTCLs). Patients and methods: Twenty-six patients with newly diagnosed PTCLs were enrolled into the pilot study. Treatment consisted of classical CHOP plus etoposide 100 mg/m2 intravenously (i.v.) on day 1 and gemcitabine 600 mg/m2 i.v. on day 1 in a 3 week interval. Results: Fifteen complete responses (CR, 57.7%) or one unconfirmed complete response (uCR, 3.8%) and four partial responses (PR, 15.4%) were confirmed, giving an overall response rate of 76.9% (95% CI, 58.3–96.3%). Median survival has not yet been reached, while median event free survival was 215 days at a median follow-up duration of 383 days. Estimated overall survival at 1 year was 69.6%. The most severe haematological adverse event was neutropaenia, which occurred with a grade 4 intensity in 14 patients (53.8%). Additionally, febrile neutropaenia was observed in four patients (15.4%). However, there was no treatment-related death. Conclusion: The CHOP-EG regimen was found to be feasible in patients with PTCLs. For further investigation on the role of gemcitabine in the treatment of PTCLs, a more large scale phase II or phase III study is warranted.
- Publication
Cancer Chemotherapy & Pharmacology, 2006, Vol 58, Issue 1, p35
- ISSN
0344-5704
- Publication type
Academic Journal
- DOI
10.1007/s00280-005-0136-y